Trial Profile
A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhoea
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Jan 2019
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Diarrhoea
- Focus Therapeutic Use
- Acronyms MEDARD
- Sponsors Ipsen
- 13 Jul 2016 Results published in the Clinical Therapeutics
- 28 Mar 2014 New trial record
- 07 Oct 2013